Global Markets Direct’s, ‘Pancreatic Cancer – Pipeline Review, H2 2015′, provides an overview of the Pancreatic Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Pancreatic Cancer
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Pancreatic Cancer and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Pancreatic Cancer
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Pancreatic Cancer pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
Introduction 12
Pancreatic Cancer Overview 13
Therapeutics Development 14
Pancreatic Cancer - Therapeutics under Development by Companies 16
Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes 40
Pancreatic Cancer - Pipeline Products Glance 43
Pancreatic Cancer - Products under Development by Companies 47
Pancreatic Cancer - Products under Investigation by Universities/Institutes 78
Pancreatic Cancer - Companies Involved in Therapeutics Development 82
Pancreatic Cancer - Therapeutics Assessment 348
Drug Profiles 414
Pancreatic Cancer - Recent Pipeline Updates 1241
Pancreatic Cancer - Dormant Projects 1675
Pancreatic Cancer - Discontinued Products 1700
Pancreatic Cancer - Product Development Milestones 1706
Appendix 1714

List of Tables

Number of Products under Development for Pancreatic Cancer, H2 2015 68
Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H2 2015 69
Number of Products under Development by Companies, H2 2015 71
Number of Products under Development by Companies, H2 2015 (Contd..1) 72
Number of Products under Development by Companies, H2 2015 (Contd..2) 73
Number of Products under Development by Companies, H2 2015 (Contd..3) 74
Number of Products under Development by Companies, H2 2015 (Contd..4) 75
Number of Products under Development by Companies, H2 2015 (Contd..5) 76
Number of Products under Development by Companies, H2 2015 (Contd..6) 77
Number of Products under Development by Companies, H2 2015 (Contd..7) 78
Number of Products under Development by Companies, H2 2015 (Contd..8) 79
Number of Products under Development by Companies, H2 2015 (Contd..9) 80
Number of Products under Development by Companies, H2 2015 (Contd..10) 81
Number of Products under Development by Companies, H2 2015 (Contd..11) 82
Number of Products under Development by Companies, H2 2015 (Contd..12) 83
Number of Products under Development by Companies, H2 2015 (Contd..13) 84
Number of Products under Development by Companies, H2 2015 (Contd..14) 85
Number of Products under Development by Companies, H2 2015 (Contd..15) 86
Number of Products under Development by Companies, H2 2015 (Contd..16) 87
Number of Products under Development by Companies, H2 2015 (Contd..17) 88
Number of Products under Development by Companies, H2 2015 (Contd..18) 89
Number of Products under Development by Companies, H2 2015 (Contd..19) 90
Number of Products under Development by Companies, H2 2015 (Contd..20) 91
Number of Products under Development by Companies, H2 2015 (Contd..21) 92
Number of Products under Development by Companies, H2 2015 (Contd..22) 93
Number of Products under Investigation by Universities/Institutes, H2 2015 94
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 95
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 96
Comparative Analysis by Late Stage Development, H2 2015 97
Comparative Analysis by Clinical Stage Development, H2 2015 98
Comparative Analysis by Early Stage Development, H2 2015 99
Comparative Analysis by Unknown Stage Development, H2 2015 100
Products under Development by Companies, H2 2015 101
Products under Development by Companies, H2 2015 (Contd..1) 102
Products under Development by Companies, H2 2015 (Contd..2) 103
Products under Development by Companies, H2 2015 (Contd..3) 104
Products under Development by Companies, H2 2015 (Contd..4) 105
Products under Development by Companies, H2 2015 (Contd..5) 106
Products under Development by Companies, H2 2015 (Contd..6) 107
Products under Development by Companies, H2 2015 (Contd..7) 108
Products under Development by Companies, H2 2015 (Contd..8) 109
Products under Development by Companies, H2 2015 (Contd..9) 110
Products under Development by Companies, H2 2015 (Contd..10) 111
Products under Development by Companies, H2 2015 (Contd..11) 112
Products under Development by Companies, H2 2015 (Contd..12) 113
Products under Development by Companies, H2 2015 (Contd..13) 114
Products under Development by Companies, H2 2015 (Contd..14) 115
Products under Development by Companies, H2 2015 (Contd..15) 116
Products under Development by Companies, H2 2015 (Contd..16) 117
Products under Development by Companies, H2 2015 (Contd..17) 118
Products under Development by Companies, H2 2015 (Contd..18) 119
Products under Development by Companies, H2 2015 (Contd..19) 120
Products under Development by Companies, H2 2015 (Contd..20) 121
Products under Development by Companies, H2 2015 (Contd..21) 122
Products under Development by Companies, H2 2015 (Contd..22) 123
Products under Development by Companies, H2 2015 (Contd..23) 124
Products under Development by Companies, H2 2015 (Contd..24) 125
Products under Development by Companies, H2 2015 (Contd..25) 126
Products under Development by Companies, H2 2015 (Contd..26) 127
Products under Development by Companies, H2 2015 (Contd..27) 128
Products under Development by Companies, H2 2015 (Contd..28) 129
Products under Development by Companies, H2 2015 (Contd..29) 130
Products under Development by Companies, H2 2015 (Contd..30) 131
Products under Investigation by Universities/Institutes, H2 2015 132
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 133
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 134
Products under Investigation by Universities/Institutes, H2 2015 (Contd..3) 135
Pancreatic Cancer - Pipeline by 3-V Biosciences, Inc., H2 2015 136
Pancreatic Cancer - Pipeline by 3B Pharmaceuticals GmbH, H2 2015 137
Pancreatic Cancer - Pipeline by 4SC AG, H2 2015 138
Pancreatic Cancer - Pipeline by AB Science SA, H2 2015 139
Pancreatic Cancer - Pipeline by AbbVie Inc., H2 2015 140
Pancreatic Cancer - Pipeline by AbGenomics International, Inc., H2 2015 141
Pancreatic Cancer - Pipeline by Ability Pharma, SL, H2 2015 142
Pancreatic Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015 143
Pancreatic Cancer - Pipeline by ACF Pharmaceuticals, LLC, H2 2015 144
Pancreatic Cancer - Pipeline by Adamed Sp. z o.o., H2 2015 145
Pancreatic Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H2 2015 146
Pancreatic Cancer - Pipeline by Aduro BioTech, Inc., H2 2015 147
Pancreatic Cancer - Pipeline by Advantagene, Inc., H2 2015 148
Pancreatic Cancer - Pipeline by Advaxis, Inc., H2 2015 149
Pancreatic Cancer - Pipeline by Agenus, Inc., H2 2015 150
Pancreatic Cancer - Pipeline by AGV Discovery, SAS, H2 2015 151
Pancreatic Cancer - Pipeline by AIMM Therapeutics B.V., H2 2015 152
Pancreatic Cancer - Pipeline by Alchemia Limited, H2 2015 153
Pancreatic Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2015 154
Pancreatic Cancer - Pipeline by Allinky Biopharma, H2 2015 155
Pancreatic Cancer - Pipeline by Almac Discovery Limited, H2 2015 156
Pancreatic Cancer - Pipeline by Altor BioScience Corporation, H2 2015 157
Pancreatic Cancer - Pipeline by Ambrx, Inc., H2 2015 158
Pancreatic Cancer - Pipeline by Amgen Inc., H2 2015 159
Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp., H2 2015 160
Pancreatic Cancer - Pipeline by Andarix Pharmaceuticals, Inc., H2 2015 161
Pancreatic Cancer - Pipeline by ANP Technologies, Inc., H2 2015 162
Pancreatic Cancer - Pipeline by APEIRON Biologics AG, H2 2015 163
Pancreatic Cancer - Pipeline by Apexigen, Inc., H2 2015 164
Pancreatic Cancer - Pipeline by Aphios Corporation, H2 2015 165
Pancreatic Cancer - Pipeline by APIM Therapeutics AS, H2 2015 166
Pancreatic Cancer - Pipeline by Apogenix GmbH, H2 2015 167
Pancreatic Cancer - Pipeline by Aposense Ltd., H2 2015 168
Pancreatic Cancer - Pipeline by Arch Biopartners, Inc., H2 2015 169
Pancreatic Cancer - Pipeline by Argon Pharma S.L., H2 2015 170
Pancreatic Cancer - Pipeline by ArQule, Inc., H2 2015 171
Pancreatic Cancer - Pipeline by Array BioPharma Inc., H2 2015 172
Pancreatic Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2015 173
Pancreatic Cancer - Pipeline by Astellas Pharma Inc., H2 2015 174
Pancreatic Cancer - Pipeline by AstraZeneca Plc, H2 2015 175
Pancreatic Cancer - Pipeline by ATLAB Pharma SAS, H2 2015 176
Pancreatic Cancer - Pipeline by Aurigene Discovery Technologies Limited, H2 2015 177
Pancreatic Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 178
Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H2 2015 179
Pancreatic Cancer - Pipeline by Azaya Therapeutics, Inc., H2 2015 180
Pancreatic Cancer - Pipeline by Basilea Pharmaceutica AG, H2 2015 181
Pancreatic Cancer - Pipeline by Bavarian Nordic A/S, H2 2015 182
Pancreatic Cancer - Pipeline by Bayer AG, H2 2015 183
Pancreatic Cancer - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015 184
Pancreatic Cancer - Pipeline by BerGenBio AS, H2 2015 185
Pancreatic Cancer - Pipeline by Beta Pharma, Inc., H2 2015 186
Pancreatic Cancer - Pipeline by Bexion Pharmaceuticals, LLC., H2 2015 187
Pancreatic Cancer - Pipeline by Biomar Microbial Technologies, H2 2015 188
Pancreatic Cancer - Pipeline by Biomunex Pharmaceuticals, H2 2015 189
Pancreatic Cancer - Pipeline by Bioncotech Therapeutics S.L., H2 2015 190
Pancreatic Cancer - Pipeline by Bionomics Limited, H2 2015 191
Pancreatic Cancer - Pipeline by BiOrion Technologies B.V., H2 2015 192
Pancreatic Cancer - Pipeline by Biotest AG, H2 2015 193
Pancreatic Cancer - Pipeline by Biothera, Inc., H2 2015 194
Pancreatic Cancer - Pipeline by Biouniversa s.r.l., H2 2015 195
Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015 196
Pancreatic Cancer - Pipeline by Boston Biomedical, Inc., H2 2015 197
Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015 198
Pancreatic Cancer - Pipeline by Calithera Biosciences, Inc., H2 2015 199
Pancreatic Cancer - Pipeline by Cantex Pharmaceuticals, Inc., H2 2015 200
Pancreatic Cancer - Pipeline by Cavion LLC, H2 2015 201
Pancreatic Cancer - Pipeline by Celgene Corporation, H2 2015 202
Pancreatic Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2015 203
Pancreatic Cancer - Pipeline by Cellectis S.A., H2 2015 204
Pancreatic Cancer - Pipeline by Celsion Corporation, H2 2015 205
Pancreatic Cancer - Pipeline by Centrose LLC, H2 2015 206
Pancreatic Cancer - Pipeline by Ceronco Biosciences, H2 2015 207
Pancreatic Cancer - Pipeline by ChemoCentryx, Inc., H2 2015 208
Pancreatic Cancer - Pipeline by Chiome Bioscience, Inc., H2 2015 209
Pancreatic Cancer - Pipeline by Clovis Oncology, Inc., H2 2015 210
Pancreatic Cancer - Pipeline by Coare Biotechnology, Inc., H2 2015 211
Pancreatic Cancer - Pipeline by Concordia Healthcare Corp., H2 2015 212
Pancreatic Cancer - Pipeline by Confluence Life Sciences, Inc., H2 2015 213
Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2015 214
Pancreatic Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2015 215
Pancreatic Cancer - Pipeline by CritiTech, Inc., H2 2015 216
Pancreatic Cancer - Pipeline by CrystalGenomics, Inc., H2 2015 217
Pancreatic Cancer - Pipeline by CTI BioPharma Corp., H2 2015 218
Pancreatic Cancer - Pipeline by CureFAKtor Pharmaceuticals, LLC, H2 2015 219
Pancreatic Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015 220
Pancreatic Cancer - Pipeline by CytomX Therapeutics, Inc., H2 2015 221
Pancreatic Cancer - Pipeline by CytoVac A/S, H2 2015 222
Pancreatic Cancer - Pipeline by CytRx Corporation, H2 2015 223
Pancreatic Cancer - Pipeline by CyTuVax B.V., H2 2015 224
Pancreatic Cancer - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015 225
Pancreatic Cancer - Pipeline by DEKK-TEC, Inc., H2 2015 226
Pancreatic Cancer - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2015 227
Pancreatic Cancer - Pipeline by e-Therapeutics Plc, H2 2015 228
Pancreatic Cancer - Pipeline by Eisai Co., Ltd., H2 2015 229
Pancreatic Cancer - Pipeline by Eleison Pharmaceuticals LLC, H2 2015 230
Pancreatic Cancer - Pipeline by Eli Lilly and Company, H2 2015 231
Pancreatic Cancer - Pipeline by Endor Nanotechnologies SL, H2 2015 232
Pancreatic Cancer - Pipeline by Ensol Biosciences Inc., H2 2015 233
Pancreatic Cancer - Pipeline by Erytech Pharma SA, H2 2015 234
Pancreatic Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2015 235
Pancreatic Cancer - Pipeline by Etubics Corporation, H2 2015 236
Pancreatic Cancer - Pipeline by Exelixis, Inc., H2 2015 237
Pancreatic Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 238
Pancreatic Cancer - Pipeline by FibroGen, Inc., H2 2015 239
Pancreatic Cancer - Pipeline by Five Prime Therapeutics, Inc., H2 2015 240
Pancreatic Cancer - Pipeline by Fountain Biopharma Inc., H2 2015 241
Pancreatic Cancer - Pipeline by Fujifilm Corporation, H2 2015 242
Pancreatic Cancer - Pipeline by Fusion Antibodies Limited, H2 2015 243
Pancreatic Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2015 244
Pancreatic Cancer - Pipeline by Genelux Corporation, H2 2015 245
Pancreatic Cancer - Pipeline by Genentech, Inc., H2 2015 246
Pancreatic Cancer - Pipeline by Genmab A/S, H2 2015 247
Pancreatic Cancer - Pipeline by Gilead Sciences, Inc., H2 2015 248
Pancreatic Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015 249
Pancreatic Cancer - Pipeline by Globeimmune, Inc., H2 2015 250
Pancreatic Cancer - Pipeline by GlycoMimetics, Inc., H2 2015 251
Pancreatic Cancer - Pipeline by Golden Biotechnology Corp., H2 2015 252
Pancreatic Cancer - Pipeline by Halozyme Therapeutics, Inc., H2 2015 253
Pancreatic Cancer - Pipeline by HanAll Biopharma Co., Ltd., H2 2015 254
Pancreatic Cancer - Pipeline by Heat Biologics, Inc., H2 2015 255
Pancreatic Cancer - Pipeline by HEC Pharm Co., Ltd., H2 2015 256
Pancreatic Cancer - Pipeline by Helix BioPharma Corp., H2 2015 257
Pancreatic Cancer - Pipeline by Huabo Biopharm Co., Ltd., H2 2015 258
Pancreatic Cancer - Pipeline by iCeutica, Inc., H2 2015 259
Pancreatic Cancer - Pipeline by Ignyta, Inc., H2 2015 260
Pancreatic Cancer - Pipeline by Immodulon Therapeutics Ltd., H2 2015 261
Pancreatic Cancer - Pipeline by Immune Pharmaceuticals Inc., H2 2015 262
Pancreatic Cancer - Pipeline by Immunomedics, Inc., H2 2015 263
Pancreatic Cancer - Pipeline by Immunotope, Inc., H2 2015 264
Pancreatic Cancer - Pipeline by Immunovo BV, H2 2015 265
Pancreatic Cancer - Pipeline by Incuron, LLC, H2 2015 266
Pancreatic Cancer - Pipeline by Incyte Corporation, H2 2015 267
Pancreatic Cancer - Pipeline by Inflection Biosciences Limited, H2 2015 268
Pancreatic Cancer - Pipeline by Innopharmax Inc., H2 2015 269
Pancreatic Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015 270
Pancreatic Cancer - Pipeline by Intica Biomedical, Inc., H2 2015 271
Pancreatic Cancer - Pipeline by Inventiva SAS, H2 2015 272
Pancreatic Cancer - Pipeline by Io Therapeutics, Inc., H2 2015 273
Pancreatic Cancer - Pipeline by Ipsen S.A., H2 2015 274
Pancreatic Cancer - Pipeline by Isarna Therapeutics GmbH, H2 2015 275
Pancreatic Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H2 2015 276
Pancreatic Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2015 277
Pancreatic Cancer - Pipeline by Kadmon Corporation, LLC, H2 2015 278
Pancreatic Cancer - Pipeline by KAEL-GemVax Co., Ltd., H2 2015 279
Pancreatic Cancer - Pipeline by Kalos Therapeutics, Inc., H2 2015 280
Pancreatic Cancer - Pipeline by Kancera AB, H2 2015 281
Pancreatic Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 282

List of Figures

Number of Products under Development for Pancreatic Cancer, H2 2015 68
Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H2 2015 69
Number of Products under Development by Companies, H2 2015 70
Number of Products under Investigation by Universities/Institutes, H2 2015 94
Comparative Analysis by Late Stage Development, H2 2015 97
Comparative Analysis by Clinical Stage Development, H2 2015 98
Comparative Analysis by Early Stage Products, H2 2015 99
Assessment by Monotherapy Products, H2 2015 402
Assessment by Combination Products, H2 2015 403
Number of Products by Top 10 Targets, H2 2015 404
Number of Products by Stage and Top 10 Targets, H2 2015 404
Number of Products by Top 10 Mechanism of Actions, H2 2015 444
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 444
Number of Products by Top 10 Routes of Administration, H2 2015 464
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 464
Number of Products by Top 10 Molecule Types, H2 2015 466
Number of Products by Stage and Top 10 Molecule Types, H2 2015 466